

## 11 Spastische verlamming, slappe verlamming, contractuurvorming

### Literatuur

- Abel NA, Smith RA. Intrathecal baclofen for intractable spinal spasticity. *Arch Phys Med Rehabil* 1994; 75: 54-8.
- Alfieri V. Electrical treatment of spasticity. *Scand J Rehabil* 1982; 14: 177-82.
- Azouvi P, Mane M, Thiebaut JP, Denys P, Remy-Neris O, Bussel B. Intrathecal Administration for Control of Severe Spinal Spasticity. Functional Improvement and Long-Term Follow-Up. *Arch Phys Med Rehabil* 1996; 75: 35-9.
- Basmaïjan JV, Super G. Dantrolene Sodium in the treatment of spasticity. *Arch Phys Med Rehabil* 1973; 54: 60.
- Basmaïjan JV, Yucel V. Effects of a GABA-derivative (BA-34647) on spasticity. *Am J Phys Med* 1974; 53: 223.
- Beckers DML, Buck MJI, Pons C. *De revalidatie van dwarslaesiepatiënten*. Lochem: De Tijdstroom; 1992.
- Bohannon RW, Larkin PA. Cybex II isokinetic dynamometer for the documentation of spasticity. *Phys Ther* 1985; 65: 46.
- Bohannon RW, Smith MB. Interrator of a modified Ashworth Scale of muscle spasticity. *Phys Ther* 1986; 67: 206-7.
- Brattstrom M, Moritz U, Svantesson G. Electromyographic studies of peripheral nerve block with phenol. *Scand J Rehabil Med* 1970; 2: 17-22.
- Brown P. Pathophysiology of spasticity [Editorial]. *J Neurol Neurosurg Psychiatry* 1994; 57: 773-7.
- Cava TJ. Botulinum toxin management of spasticity in upper motor neuron lesions. *Eur J Neurol* 1995; 2 Suppl 3: 57-60.
- Davidoff RA. Mode of action of antispasticity drugs. *Neurosurgery: State of the art reviews* 1989; 4: 315.
- Davies J. Selective depression of synaptic transmission of spinal neurons in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolyl-amino)-2,1,3-benzothiazole (DS103-282). *Br J Pharmacol* 1982; 76: 483.
- Delwaide PJ. Electrophysiological analysis of the mode of action of muscle relaxants in spasticity. *Ann Neurol* 1985; 17: 90.
- Douglas AF, Weiner HL, Schwartz DR. Prolonged intrathecal baclofen withdrawal syndrome. Case report and discussion of current therapeutic management. *J Neurosurg* 2005; 102: 1133-6.
- Gans MB, Glenn MB. Introduction. In: Glenn MB, Whyte J, editors. *The practical management of spasticity in children and adults*. Philadelphia: Lea & Febiger; 1990.
- Gantmacher J. Oral vs intrathecal baclofen. Toxicity of baclofen. *Interventional Spasticity Therapies workshop. European Continuing Medical Training*. Genk; 1996.

## Handboek dwarslaesierevalidatie

- Goff B. Grading of spasticity and its effect on voluntary movement. *Physiotherapy* 1976; 62: 358-61.
- Gottlieb GL, Atarwal GC, Penn R. Sinusoidal oscillation of the ankle as a means of evaluating the spastic patiënt. *J Neurol Neurosurg Psychiatry* 1978; 41: 32.
- Gottlieb GL, Myklebust BM, Stefoski D et al. Evaluation of cervical stimulation for chronic treatment of spasticity. *Neurology* 1985; 35: 699-704.
- Granger CV et al. Advances in functional assessment for medical rehabilitation. *Top Geriat Rehabil* 1986; 59: 1.
- Haley SM, Inacio CA. Evaluation of spasticity and its effect on motor function management. In: Glenn MB, Whyte J, editors. *The practical management of spasticity in children and adults*. Philadelphia: Lea & Febiger; 1990. 70-96.
- Halpern D et al. Muscular hypertonia. Quantitative analysis. *Arch Phys Med Rehabil* 1979; 60: 208.
- Halpern D. Histologic studies in animals after intramuscular neurolysis with phenol. *Arch Phys Med Rehabil* 1977; 58: 438-43.
- Hermens HJ. Surface Emg, PH.D.-Thesis. *Journal of Rehabilitation Sciences* 1992; 3: 90-1.
- Illis LS. *Management of Spasticity. Neurological Rehabilitation*. Oxford: Blackwell Scientific Publications; 1994. 335-48.
- Jones RF, Burke D, Marosszeky JE, Gillies JD. A new agent for the control of spasticity. *J Neurol Neurosurg Psychiatry* 1970; 33: 464.
- Katz RT. Management in spasticity. In: Braddom RL, editor. *Physical Medicine & Rehabilitation*. Philadelphia: Saunders Company; 1996. 581-604.
- Katz RT. Spasticity. In: O`Young B, Young MA, Stiens SA, editors. *PM & R Secrets*. Philadelphia: Henly & Belfus; 1997.
- Katz RT, Rymer WJ. Spastic hypertonia. Mechanisms and measurement. *Arch Phys Med Rehabil* 1989; 70: 144.
- Khalili AA, Harmel MH, Forster S, Benton JG. Mangement of spasticity by selective peripheral nerve block with dilute phenol solutions in clinical rehabilitation. *Arch Phys Med Rehabil* 1964; 45: 513-9.
- Knutsson E. Quantification of spasticity. In: Strappler A, Weindl A, editors. *Electromyography and Evoked potentials*. Berlin: Springer-Verlag; 1985.
- Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. *Spasticity. Disordered motor control*. Chicago: Chicago Yearbook Medical Publications; 1980. 485-94.
- Maynard FM. Early clinical experience with clonidine in spinal spasticity. *Paraplegia* 1986; 24: 175.
- McLean BN. Intrathecal baclofen in severe spasticity. *British Journal of Hospital Medicine* 1993; 49: 262-7.

## Handboek dwarslaesierevalidatie

- Merrit JL. Management of spasticity in spinal cord injury. *Mayo Clin Proc* 1981; 56: 614-22.
- Michaelis LS. Spasticity in spinal cord injuries. In: Vinken PJ, Bruyn GW, editors. *Handbook of Clinical Neurology*. Amsterdam; 1976. 447-87.
- Middleton JW, Siddall PJ, Walker S. Intrathecal Clonidine and Baclofen in the Management of Spasticity and Neuropathic Pain Following Spinal Cord Injury. A Case Study. *Arch Phys Med Rehabil* 1996; 77: 824-6.
- Millet MF, Mortamais J, Sindou M et al. In: Simon L, editor. *Actualité en Reeduction fonctionelle et readaptation*. Paris: Masson; 1981. 76-85.
- Moore AP. General and clinical aspects of treatment with botulinum toxin. In: Moore P, editor. *Handbook of botulinum toxin treatment*. Oxford: Blackwell Science; 1995.
- Nance PW, Shears AH, Nance DM. Clonidine in spinal cord injury. *Can Med Assoc. J* 1985; 133: 41-2.
- Oosterhuis HJGH. *Klinische neurologie*. 11e ed. Houten: Bohn Stafleu van Loghum; 1992. 18-37.
- Penn RD, Kroin JS. Continuous intrathecal Baclofen for severe spasticity. *Lancet* 1985; 20: 125-7.
- Penn RD, Kroin JS. Intrathecal Baclofen alleviates spinal cord spasticity. *Lancet* 1984; 1: 1078.
- Petrillo CR, Chu DS, Davis SW. Phenol block on the tibial nerve in the hemiplegic patient. *Orthopedics* 1980; 3: 871-4.
- Pirotte B, Wesel P, Heilporn A, Brotchi J. *Clinical assessment of severe spasticity. Interventional Spasticity Therapies workshop. European Continuing Medical Training*. Genk; 1996.
- Priebe MM, Sherwood AM, Graves DE. Effectiveness of gabapentin in controlling spasticity. A quantitative study. *Spinal Cord* 1997; 35: 171-5.
- Priebe MM, Sherwood AM, Thonby JI, Kharas NF, Markowski J. Clinical Assessment of Spasticity in Spinal Cord Injury. A Multidimensional Problem. *Arch Phys Med Rehabil* 1996; 77: 713-6.
- Satkunam LE. Rehabilitation medicine. 3. Management of adult spasticity. Review. *Can Med Assoc J* 2003; 11: 1173.
- Stein AB, Pomerantz F, Schechtman J. Evaluation and Management of spasticity in Spinal Cord Injury. *Top Spinal Cord Inj Rehabil* 1997; 70-83.
- Voth EA, Schwartz RH. Medicinal applications of Delta-9-Tetrahydrocannabinol and Marijuana. *Ann Intern Med* 1997; 126: 791-8.
- Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. *Neurology* 1994; 44 Suppl 9: S60-S69.
- Wartenberg R: Pendulousness of the legs as a diagnostic test. *Neurology* 1951; 1: 18.

## Handboek dwarslaesierevalidatie

Whitlock JA. Neurophysiology of spasticity. In: Glenn MB, Whyte J, editors. *The practical management of spasticity in children and adults*. Philadelphia: Lea & Febiger; 1990. 8-33.

Whyte J, Robinson KM. Pharmacologic management. In: Glenn MB, Whyte J, editors. *The practical management of spasticity in children and adults*. Philadelphia: Lea & Febiger; 1990. 1-7.

Young RR, Shahani BT. Spasticity in Spinal Cord Injured Patients. In: Bloch RF, Basbaum M, editors. *Management of Spinal Cord Injuries*. Baltimore: Williams & Wilkins; 1986. 241-83.